Gastrointestinal Obstruction with MCC DRG Reimbursement

DRG 388 encompasses inpatient stays for gastrointestinal obstruction when a Major Complication or Comorbidity is present; it includes obstructive processes that require higher-acuity care. This Diagnosis-Related Group matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases resource use and impacts Centers for Medicare & Medicaid Services payment classification and hospital case-mix index.

DRG 388 Overview

DRG 388 covers inpatient admissions for gastrointestinal obstruction with at least one Major Complication or Comorbidity present. Typical clinical cases include small-bowel or large-bowel obstruction due to adhesions, hernia, malignancy, or inflammatory causes accompanied by severe physiologic derangements or significant comorbid conditions. This Diagnosis-Related Group affects resource intensity because the Major Complication or Comorbidity often necessitates more complex diagnostics, higher-acuity medical management, or operative intervention. It is important for Centers for Medicare & Medicaid Services payment determinations and hospital case-mix reimbursement.

Acute surgical intervention trials: randomized or prospective cohort studies comparing timing and techniques of operative management (e.g., emergent laparotomy versus minimally invasive adhesiolysis or endoscopic decompression) in adults admitted with high-grade mechanical small bowel or large bowel obstruction complicated by sepsis, ischemia, or organ dysfunction. These studies enroll patients during the index hospitalization to evaluate short-term outcomes such as rates of bowel resection, perioperative mortality, ICU days, and complication rates, helping clinicians determine optimal acute management strategies. Results are highly relevant to providers for clinical decision-making and to payers because differences in intervention timing and approach directly affect length of stay, resource utilization, and costs associated with the DRG.
Comparative effectiveness and care pathway research for nonoperative versus operative management: observational studies and pragmatic trials that examine selection criteria, success rates, and downstream resource use for nonoperative strategies (nasogastric decompression, bowel rest, IV fluids, and targeted antibiotics) versus surgical intervention in patients with partial obstruction or obstruction with significant comorbidity. These studies often focus on older adults and medically complex patients who are at higher risk of major complications and prolonged hospitalization, assessing readmission rates, need for delayed surgery, functional outcomes, and total episode-of-care costs. Findings inform protocols, risk stratification, and guideline development, which help hospitals and payers optimize care pathways to reduce unnecessary operations, complications, and costly prolonged stays associated with DRG 388.
Post-discharge outcomes, rehabilitation, and readmission reduction studies: cohort studies and intervention trials that target recovery, nutritional rehabilitation, and prevention of recurrent obstruction in survivors of an index admission with gastrointestinal obstruction complicated by major complication (for example, investigations of enhanced post-discharge follow-up, structured nutrition programs, or adhesion-prevention strategies). These trials enroll patients at discharge or early outpatient follow-up to measure functional recovery, quality of life, rates of 30- and 90-day readmission, and long-term health care utilization. This research is relevant for providers to improve continuity of care and patient recovery, and for payers because reducing readmissions and post-acute complications can substantially affect overall costs attributed to the DRG.

Acute surgical intervention trials: randomized or prospective cohort studies comparing timing and techniques of operative management (e.g., emergent laparotomy versus minimally invasive adhesiolysis or endoscopic decompression) in adults admitted with high-grade mechanical small bowel or large bowel obstruction complicated by sepsis, ischemia, or organ dysfunction. These studies enroll patients during the index hospitalization to evaluate short-term outcomes such as rates of bowel resection, perioperative mortality, ICU days, and complication rates, helping clinicians determine optimal acute management strategies. Results are highly relevant to providers for clinical decision-making and to payers because differences in intervention timing and approach directly affect length of stay, resource utilization, and costs associated with the DRG.
Comparative effectiveness and care pathway research for nonoperative versus operative management: observational studies and pragmatic trials that examine selection criteria, success rates, and downstream resource use for nonoperative strategies (nasogastric decompression, bowel rest, IV fluids, and targeted antibiotics) versus surgical intervention in patients with partial obstruction or obstruction with significant comorbidity. These studies often focus on older adults and medically complex patients who are at higher risk of major complications and prolonged hospitalization, assessing readmission rates, need for delayed surgery, functional outcomes, and total episode-of-care costs. Findings inform protocols, risk stratification, and guideline development, which help hospitals and payers optimize care pathways to reduce unnecessary operations, complications, and costly prolonged stays associated with DRG 388.
Post-discharge outcomes, rehabilitation, and readmission reduction studies: cohort studies and intervention trials that target recovery, nutritional rehabilitation, and prevention of recurrent obstruction in survivors of an index admission with gastrointestinal obstruction complicated by major complication (for example, investigations of enhanced post-discharge follow-up, structured nutrition programs, or adhesion-prevention strategies). These trials enroll patients at discharge or early outpatient follow-up to measure functional recovery, quality of life, rates of 30- and 90-day readmission, and long-term health care utilization. This research is relevant for providers to improve continuity of care and patient recovery, and for payers because reducing readmissions and post-acute complications can substantially affect overall costs attributed to the DRG.

OpenPayer

Summary & Overview

Gastrointestinal Obstruction with MCC: Inpatient Reimbursement Overview

DRG 388 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes